European Primary Care Cardiovascular Society

Diabetes

Diabetes is now considered an important risk factor for cardiovascular disease, and a complex interplay of pathogenic factors complicates management of both diseases.

New EASD-ADA consensus guidelines on managing hyperglycemia in T2DM

Oct. 9, 2018 - news

Diabetes may begin more than 20 years before diagnosis

Oct. 9, 2018 - news

Importance increasing BMI from age 10 to adulthood in development T2DM

Oct. 3, 2018 - news

New EASD-ADA consensus guidelines on managing hyperglycemia in T2DM

Oct. 9, 2018 - news

EASD 2018 Following a review of the latest evidence, the EASD and the ADA introduced new recommendations on managing hyperglycemia in T2DM, including specific drug classes for some patients and enhancing medication adherence.

Diabetes may begin more than 20 years before diagnosis

Oct. 9, 2018 - news

EASD 2018 Increased fasting glucose, higher BMI and impaired insulin sensitivity were detectable up to 10 years before the diagnosis of diabetes as well as prediabetes.

Importance increasing BMI from age 10 to adulthood in development T2DM

Oct. 3, 2018 - news

EASD 2018 Weight gain between the age of 10 and adulthood is associated with T2DM risk. Overweight children at age 10 appear to be at lower risk for developing T2DM than children who are regular weight at age 10 and then later become overweight as adults.

How quickly T2DM progresses is determined by multiple factors

Oct. 3, 2018 - news

EASD 2018 A study found various clinical and biochemical factors that are associated with a greater risk of fast disease progression in T2DM patients.

CV safety with weight loss agent in high-risk overweight or obese patients

Aug. 26, 2018 - Dr. Erin Bohula, Boston, MA, US
In overweight or obese patients with CVD or diabetes with one CV risk factor, lorcaserin demonstrated to be safe with respect to CV outcomes. Dr. Bohula discussed the implications of the CAMELLIA-TIMI 61 trial.

ESC 2018 In overweight or obese patients with CVD or diabetes with one CV risk factor, lorcaserin demonstrated to be safe with respect to CV outcomes. Dr. Bohula discussed the implications of the CAMELLIA-TIMI 61 trial.

No overall benefit with aspirin in a primary prevention setting of diabetes patients

Aug. 27, 2018 - Prof. Jane Armitage, Oxford, UK
Although aspirin resulted in a reduction of CV events in a primary prevention setting of diabetes patients, this CV benefit was counterbalanced by an increase in bleeding.

ESC 2018 Although aspirin resulted in a reduction of CV events in a primary prevention setting of diabetes patients, this CV benefit was counterbalanced by an increase in bleeding.

Omega-3 fatty acid supplements do not result in CV benefits

Aug. 26, 2018 - Dr Louise Bowman, Oxford, UK
Use of omega-3 fatty acid supplements did not result in reduction of CV outcomes in the ASCEND trial, a large, randomized, long-term trial of diabetes patients.

ESC 2018 Use of omega-3 fatty acid supplements did not result in reduction of CV outcomes in the ASCEND trial, a large, randomized, long-term trial of diabetes patients.

Diabetes patients and patients with moderate CV risk do not have overall CV benefit of use of aspirin in primary prevention setting

ESC 2018 - Munich

Sep. 4, 2018 - news

ESC 2018 One large randomized trial showed that use of aspirin for primary prevention reduced CV events in a diabetes population but at the cost of bleeding, and another resulted in no CV benefit in patients with moderate CV risk.

Fish oil supplementation has no beneficial effects on vascular events or mortality in diabetic patients

ESC 2018 - Munich

Sep. 4, 2018 - news

ESC 2018 The randomized ASCEND clinical trial showed no beneficial effects of omega-3 fatty acids intake on serious vascular events and all-cause or cause-specific mortality in diabetic patients.

Summary | Practical management of cardiovascular risk: Lessons from latest diabetes trials

May 3, 2018 – Prof. Lars Rydén, MD

This is a summary of the presentation by prof. Rydén, in which he reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.

Summary | The cardiovascular challenge for primary care in diabetes

May 3, 2018 – Prof. Richard Hobbs, MD

This summary of the presentation by prof. Hobbs illustrates why diabetes poses a high burden to primary health care, since patients with T2DM are at high CV risk. This risk can be lowered by targeting various risk factors.

Practical management of cardiovascular risk: Lessons from latest diabetes trials

July 17, 2018 - Prof. Lars Rydén - Stockholm, Sweden
Prof. Rydén reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.

Prof. Rydén reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.